Inhibition of human cytochrome P450 isoforms in vitro by Zafirlukast

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 8, 1999, Pages 385-388

  Shader, Richard I ^a   Granda, Brian W ^a   Von Moltke, Lisa L ^a   Giancarlo, Gina M ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytochrome P450; Isoforms; Zafirlukast

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450; DEXTROMETHORPHAN; MEPHENYTOIN; PHENACETIN; TOLBUTAMIDE; TRIAZOLAM; WARFARIN; ZAFIRLUKAST;

ARTICLE; DRUG ACTIVITY; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER; LIVER MICROSOME;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; LEUKOTRIENE ANTAGONISTS; TOSYL COMPOUNDS;

EID: 0033366601     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(199911)20:8<385::AID-BDD203>3.0.CO;2-7     Document Type: Article

References (35)

1. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134: 273-279.
2. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
3. Tashkin DP, Nathan RA, Rowland WC, Minkwitz MC, Simonson SG, Bonuccelli CM. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. J Allergy Clin Immuno 1999; 103: 346-354.
4. Calhoun WJ. Summary of clinical trials with zafirlukast. Am J Resp Crit Care Med 1998; 157: S238-S245.
5. Kelloway JS. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma. Ann Pharmacother 1997; 31: 1012-1021.
6. Holloway J, Ferriss J, Groff J, Craig TJ, Klinek M. Churg-Strauss syndrome associated with zafirlukast. J Am Osteopath Assoc 1998; 98: 275-278.
7. Zafirlukast, In Therapeutic Drugs (2nd edn (Vol 2)). Dollery C (ed.). Churchill Livingstone: Edinburgh, 1999; Z1-Z6.
8. 4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med 1994; 150: 618-623.
9. 4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther 1993; 54: 430-436.
10. Suttle AB, Vargo DL, Wilkinson LA, Birmingham BK, Lasseter K. Effect of zafirlukast on the pharmacokinetics of R- and S-warfarin in healthy men. Clin Pharmacol Ther 1997; 61: 186 (abstract).
11. Vargo DL, Yeh C, Lasseter K, Shambien EC, Birmingham BK. Effect of zafirlukast on prothrombin time and area under the curve of warfarin. J Clin Pharmacol 1997; 37: 870 (abstract).
12. Mendez R, Venzor J, Ortiz G. Failure of zafirlukast to prevent ibuprofen-induced anaphylaxis. Ann Allergy Asthma Immunol 1998; 80: 225-226.
13. Katial RK, Stelzle RC, Bonner MW, Marino M, Cantilena LR, Smith LJ. A drug interaction between zafirlukast and theophylline. Arch Int Med 1998; 158: 1713-1715.
14. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993; 47: 268-276.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
16. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
17. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
18. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 1996; 128: 398-407.
19. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J Pharmaceut Sci 1998; 87: 1502-1507.
20. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharmaceut Sci 1998; 87: 845-853.
21. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6, 3A3/4, with a possible role of 2E1. Biopharm Drug Dispos 1997; 18: 227-240.
22. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998; 5: 997-1004.
23. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharm Pharmacol Comm 1998; 4: 443-445.
24. Court MH, von Moltke LL, Shader RI, Greenblatt DJ. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos 1997; 18: 213-226.
25. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
26. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
27. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 1999; 46: 839-849.
28. Obach RS. Nonspecific binding to microsomes. Drug Metab Dispos 1997; 25: 1359-1369.
29. Gibbs MA, Kunze KL, Howald WN, Thummel KE. Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 1999; 27: 596-599.
30. von Moltke LL, Tran TT, Venkatakrishnan K, Greenblatt DJ. In vitro microsomal binding may bias chemical inhibition data. Clin Pharmacol Ther 2000; 67: 127 (abstract).
31. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998; 55: 113-122.
32. Yamano K, Yamamoto K, Kotaki H, Sawada Y, Iga T. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 1999; 27: 395-402.
33. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, Iga T. Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats. Drug Metab Dispos 1999; 27: 1225-1231.
34. Suttle AB, Birminghan BK, Vargo DL, Wilkinson LA, Morganroth J. Pharmacokinetics of zafirlukast and terfenadine after coadministration to healthy men. J Clin Pharmacol 1997; 37: 870 (abstract).
35. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother 1999; 43: 1152-1155.